Table 1 Characteristics of 78 patients with advanced hepatocellular carcinoma who received low-dose nivolumab
From: Low-dose nivolumab in advanced hepatocellular carcinoma
Characteristics | |
|---|---|
Age (median, range) | 63 (38–81) years |
Sex | |
 Male | 61 (78.2%) |
 Female | 17 (21.8%) |
ECOG PS | |
 0 | 34 (43.6%) |
 1 | 44 (56.4%) |
Child–Pugh classification | |
 A | 58 (74.4%) |
 B (7) | 20 (25.6%) |
BCLC classification | |
 C | 78 (100%) |
ALBI grade | |
 1 | 33 (42.3%) |
 2 | 45 (57.7%) |
Viral hepatitis status | |
 Hepatitis B | 49 (62.8%) |
 Hepatitis C | 23 (29.5%) |
 No | 6 (7.7%) |
Macrovascular invasion (IVC, HV, PV) | |
 Yes | 39 (50%) |
 No | 39 (50%) |
Main portal vein thrombosis | |
 Yes | 11 (14.1%) |
 No | 67 (85.9%) |
History of hepatectomy | |
 Yes | 31 (39.7%) |
 No | 47 (60.3%) |
Extrahepatic spread | |
 Yes | 39 (50%) |
 No | 39 (50%) |
Lymph node metastasis | |
 Yes | 27 (34.6%) |
 No | 51 (65.4%) |
AFP (median, range) ng/ml | 523 (< 2.0 – > 80,000) |